Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

Cancer Science

Volumn 101, Issue 2, 2010, Pages 530-535

  Chen, Yen Chung ^a   Tzeng, Cheng Hwai ^a,b   Chen, Po Min ^a,b   Lin, Jen Kou ^a,b   Lin, Tzu Chen ^a,b   Chen, Wei Shone ^a,b   Jiang, Jeng Kae ^a,b   Wang, Huann Sheng ^a,b   Wang, Wei Shu ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE P1; OXALIPLATIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; ARTICLE; CAUCASIAN; CHINESE; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DETOXIFICATION; DRUG RESPONSE; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUTATION RATE; MUTATIONAL ANALYSIS; NEUROPATHY; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC;

EID: 75649126926     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01418.x     Document Type: Article

References (35)

1. Rixe O, Ortuzar W, Alvarez M. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996, 52:1855-65.
2. de Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-47.
3. Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-51.
4. Cassidy J, Tabernero J, Twelves C. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004, 22:2084-91.
5. Tournigand C, Cervantes A, Figer A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006, 24:394-400.
6. Wilson RH, Lehky T, Thomas RR. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767-74.
7. Extra JM, Marty M, Brienza S. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998, 25:13-22.
8. Chang PM, Tzeng CH, Chen PM. ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 2009, 100:278-83.
9. Lai JI, Tzeng CH, Chen PM. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2009, 100:1261-6.
10. Board PG, Baker RT, Chelvanayagam G. A novel class of glutathione transferases in a range of species from plants to humans. Biochem J 1997, 328:929-35.
11. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998, 19:275-80.
12. Stoehlmacher J, Park DJ, Zhang W. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004, 91:344-54.
13. Stoehlmacher J, Park DJ, Zhang W. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002, 94:936-42.
14. Sato K. Glutathione S-transferases as markers of preneoplasia and neoplasia. Adv Cancer Res 1989, 52:205-55.
15. Mir O, Alexandre J, Tran A. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009, 20:736-40.
16. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006, 12:3050-6.
17. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997, 18:641-4.
18. Chang A, Parikh P, Thongprasert S. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006, 1:847-55.
19. Liu CY, Chen PM, Chiou TJ. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008, 112:1932-40.
20. Marsh S, Collie-Duguid ES, Li T. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999, 58:310-2.
21. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995, 20:191-7.
22. Chenevix-Trench G, Young J, Coggan M, Board P. (1995) Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age at onset. Carcinogenesis 1995, 16:1655-7.
23. Lee WH, Morton RA, Epstein JL. Cytidine methylation of regulatory sequences near the Pi class glutathione S transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994, 91:11733-7.
24. Ates NA, Tamer L, Ates C. Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer. Biochem Genet 2005, 43:149-63.
25. Grolleau F, Gamelin L, Boisdron-Celle M. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001, 85:2293-7.
26. Ruzzo A, Graziano F, Loupakis F. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007, 25:1247-54.
27. Kweekel DM, Gelderblom H, Antonini NF. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 2009, 45:572-8.
28. Goto S, Iida T, Cho S, Oka M, Kohno S, Kondo T. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 1999, 31:549-58.
29. Hayes JD, Wolf CR, Townsend DM. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22:7369-77.
30. Nishimura T, Newkirk K, Sessions RB. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996, 2:1859-65.
31. Sun N, Sun X, Chen B. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2009, Jul 1. [Epub ahead of print]
32. Voso MT, Hohaus S, Guidi F. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 2008, 22:1685-91.
33. Goekkurt E, Hoehn S, Wolschke C. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients. Br J Cancer 2006, 94:281-6.
34. Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 2008, 111:93-101.
35. Kweekel DM, Koopman M, Antonini NF. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 2008, 99:1316-21.